VBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Stock Information for Arlington Asset Investment Corp Class A (new)

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Arlington Asset Investment Corp Class A (new)

Notable Labs Closes Merger Transaction With VBL Therapeutics
VBL Therapeutics Announces Results of Annual and Special Shareholder Meeting
VBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meeting
VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SEC
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VBLT, DM, AAIC
VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT
VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
VBL Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.